Macromolecular Carriers for Drug Targeting

The Practice of Medicinal Chemistry: Second Edition

Volumn , Issue , 2003, Pages 587-600

  Schacht, Etienne H ^a   De Winne, Katleen ^a   Hoste, Katty ^a   Vansteenkiste, Stefan ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE POLYMERS; CELL MEMBRANES; CHEMICAL STABILITY; CONTROLLED DRUG DELIVERY; CYTOLOGY; ENZYMES; MACROMOLECULES; MOLECULAR BIOLOGY; MOLECULAR WEIGHT;

CHEMICAL COMPOSITIONS; COVALENT COUPLINGS; ENDOSOMAL COMPARTMENTS; LOW MOLECULAR WEIGHT; PH-CONTROLLED RELEASE; POLYMERIC CARRIERS; STRUCTURE PROPERTY RELATIONSHIPS; WATERSOLUBLE POLYMERS;

TARGETED DRUG DELIVERY;

EID: 84942897050     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012744481-9/50038-6     Document Type: Chapter

References (158)

1. Controlled Drug Delivery: Fundamentals and Applications 1987, Marcel Dekker, Wien. 2nd edn. J.R. Robinson, H.L. Lee (Eds.).
2. Duncan R., Seymour L.W. Controlled Release Technologies: A Survey of Research and Commercial Applications 1989, Elsevier Advanced Technology, New York.
3. Kim S.W., Kopecek J., Knutsen K. Advances in Drug Delivery Systems 1992, Part 5, Elsevier, Oxford. J.M. Anderson (Ed.).
4. Kim S.W., Kopecek J., Knutsen K. Advances in Drug Delivery Systems 1994, Part 6, Elsevier, Amsterdam. J.M. Anderson (Ed.).
5. Baker R. Controlled Release of Biologically Active Agents 1987, Wiley, Amsterdam.
6. Vert M. Polyvalent polymeric drug carriers. CRC Crit. Rev. Ther. Drug Carrier Syst. 1986, 2:291-327.
7. Okano T., Yui N., Yokoyama M., Yoshida R. Advances in Polymeric Systems for Drug Delivery 1994, Gordon and Breach Science Publisher, Gordon and Breach Science Publisher, New York.
8. Barry B.W. Drug delivery systems. CHEMTECH 1983, 38-44.
9. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Symp. 1975, 51:135-153.
10. Donaruma L.G. Synthetic biologically active polymers. Prog. Polym. Sci. 1974, 4:1-25.
11. Batz H.G. Polymeric drugs. Adv. Polym. Sci. 1977, 23:25-53.
12. Ottenbrite R.M. Introduction to biology and medicine. Anionic Polymeric Drugs 1980, Wiley, Tokyo. L.G. Donaruma, R.M. Ottenbrite, O. Vogl (Eds.).
13. Duncan R., Kopecek J. Soluble synthetic polymers as potential drug carriers. Adv. Polym. Sci. 1984, 57:51-101.
14. Ferruti P., Tanzi M.C. New polymeric and oligomeric matrices as drug carriers. CRC Crit. Rev. Ther. Drug Carrier Syst. 1986, 2:175-244.
15. Kim S.W., Peterson R.V., Feijen J. Polymeric drug delivery systems. Drug Design 1980, vol. X:193-250. Academic Press, New York. E. Arlens (Ed.).
16. Kopecek J., Rejmanova P., Duncan R., Lloyd J.B. Controlled release of drug model from N-(2-hydroxypropyl)methacrylamide copolymers. Ann. NY Acad. Sci. 1985, 446:93-104.
17. Rihova B., Ulbrich K., Strohalm J., Vetvicka V., Bilej M., Duncan R., Kopecek J. Biocompatibility of N-(2-hydroxypropyl)-methacrylamide copolymers containing adriamycin. Immunogenicity, effect on hematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials 1989, 10:335-342.
18. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 1992, 3:175-210.
19. Pato J., Azori M., Tudos F. Quinidine convalently bound to a dextran carrier. J. Bioact. Biocomp. Polymers 1987, 2:142-147.
20. Mora M., Pato J., Tudos F. Polymeric prodrugs, 6. Synthesis and examination of 6-purinethiol bound to poly(1-vinyl-2-pyrrolidone-co-maleic acid). Makromol. Chem. 1989, 190:1967-1974.
21. Soutif J.C., Mouity-Moussounda F., Brosse J.C. Polymeric carriers of glycerol derivatives, 2. Chlorambucil derivatives. Makromol. Chem. Rapid Commun. 1983, 4:61-64.
22. Yasuhiro M., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumourotropic accumulation of proteins and the antitumour agent smancs. Cancer Res. 1986, 46:6387-6392.
23. Hirano T., Ringsdorf H., Zaharko D.Z. Antitumour activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. Cancer Res. 1980, 40:2263-2267.
24. Przybylski E., Fell E., Ringsdorf H., Zaharko D.Z. Pharmacologically active polymers. 17. Synthesis and characterization of polymeric derivatives of the antitumour agent methotrexate. Makromol. Chem. 1978, 179:1719-1733.
25. Remon J.P., Duncan R., Schacht E. Polymer-drug combinations: pinocytic uptake of modified polysaccharides containing procaimide moieties by rat visceral yolk sacs cultured in vitro. J. Controlled Rel. 1984, 1:47-56.
26. Schacht E. Use of polysaccharides as drug carriers. Ann. Natl Acad. Sci. USA 1985, 446:199-212.
27. Bernstein A., Hurwitz E., Maron R., Arnon R., Sela M., Wilchek M. Higher antitumour efficacy of daunomycin when linked to dextran, in vivo and in vitro studies. J. Natl Cancer Inst. 1978, 60:379-384.
28. Konieezny M., Charytonowicz D., Inglot A.D. Search for carriers for non-covalent binding of interferon among 1,3,5-triazine derivatives of dextran. Arch. Immunol. Ther. Exp. 1982, 30:1-10.
29. Sezaki H., Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Therapeut. Drug Carr. Syst. 1984, 1:1-38.
30. Matsumoto S., Yamamoto A., Takakura Y., Hashida M., Sezaki H. Cellular interaction and in vitro antitumour activity of mitomycin C-dextran conjugate. Cancer Res. 1986, 46:4463-4468.
31. Molteni L. Dextrans as drug carriers. Drug Carriers in Biology and Medicine 1979, 107-125. Academic Press, New York. G. Gregoriadis (Ed.).
32. Simonescu C.R., Popa M.I., Dimitriu S. Bioactive polymers. XIV. Immobilization of ampicillin on biozan R. Z. Naturforsch. 1984, 39C:397-401.
33. Hurwitz E., Wilchek M., Pitha J. Soluble macromolecules as carriers of daunomycin. J. Appl. Biochem. 1980, 2:25-36.
34. Ouchi Y., Banba T., Matsumoto T., Suzuki S., Suzuki M. Antitumour activity of chitosan and chitin immobilized 5-fluorouracils through hexamethylene spacers via carbamoyl bonds. J. Bioact. Biocomp. Pol. 1989, 4:362-371.
35. Ryser H., Shen W.C. Conjugation of methotrexate to poly(1-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc. Natl Acad. Sci. USA 1978, 75:3867-3870.
36. Zunino F., Giulliani F., Savi G., Dasdia T., Gambetta R. Anti-tumour activity of daunorubicin linked to poly-L-aspartic acid. J. Pharmacol. Exp. Ther. 1982, 30:465-469.
37. Giammona G., Puglisi G., Carlisi B., Pignatello R., Spadaro A., Caruso A. Polymeric prodrugs: α-β-poly(N-hydroxyethyl)-DL-aspartamide as macromolecular carrier for some non-steroidal antiinflammatory agents. Int. J. Pharm. 1989, 57:55-62.
38. Friedmann G., Aichaoui H., Brini M. Polymères à propriétés pharmacologiques potentiels: greffage par liaison amide et (ou) ester d'un hypoglycémiant. Makromol. Chem. 1981, 182:337-347.
39. De Machado M., Neuse E.W., Perlwitz A.G. Water-soluble polyamides as potential drug carriers. V. Carboxy-functionalized polyaspartamides and copolyaspartamides. Angew. Makromol. Chem. 1992, 195:35-56.
40. De Marre A., Soyez H., Schacht E. Synthesis of macromolecular mitomycin C derivatives. J. Controlled Release 1994, 32:129-137.
41. Trouet A., Baurain R., Deprez-De Campaneere D., Pirson P. Targeting of antitumoral antiprotozoal drugs by covalent linkage to protein carriers. Targeting of Drugs 1982, 19-30. Plenum Press, London. G. Gregoriadis, J. Senior, A. Trouet (Eds.).
42. Chu B.C.F., Whiteley J.M. Control of solid tumour metastases with a high molecular weight derivative of methotrexate. J. Natl Cancer Inst. 1979, 62:79-82.
43. Harris J.M. Introduction to biotechnical and biomedical applications of poly(ethylene glycol). Poly (ethylene glycol) Chemistry: Biotechnical and Biomedical Applications 1992, 1-14. Plenum Press, New York. J.M. Harris (Ed.).
44. Abuchowski A., Es T.V., Palczuk N.C., Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 1977, 252:3578-3581.
45. Abuchowski A., Kazo G.M., Verhoest C.R., Van Es T., et al. Cancer Therapy with chemically modified enzymes. 1. A property of polyethylene glycol asparaginase conjugates. Cancer Bio. Chem. Biophys. 1984, 7:175-186.
46. Abuchowski A., Davis F.F. Enzymes as Drugs 1981, Wiley, New York. J. Hosenberg, J. Roberts (Eds.).
47. Cecchi R., Rusconi L., Tanzi M.C., Danusso F., Ferruti P. Synthesis and Pharmacological evaluation of 4-isobutylphenyl-2-propionic acid (ibuprofen). J. Med. Chem. 1981, 24:622-625.
48. Duncan R., Kopecek J., Lloyd J.B. Development of N-(2-hydroxypropyl)-methacrylamide copolymers as carriers of therapeutic agents. Polymers in Medicine: Biomedical and Pharmacological Applications 1983, 97-114. Plenum Press, New York. E. Chiellini, P. Guisti (Eds.).
49. Lloyd J.B., Duncan R., Pratten M.K. Soluble synthetic polymers as targetable agents for intracellular drug release. Br. Polym. J. 1983, 15:158-159.
50. Duncan R., Kopecek J., Rejmanova P., Lloyd J.B. Targeting of N-(2-hydroxypropyl)-methacrylamide copolymers to liver by incorporation of galactose residues. Biochem. Biophys. Acta 1983, 755:518-521.
51. Seymour L.W., Flanagan P.A., Al-Shamkhani A., Subr V., Ulbrich K., Cassidy J., Duncan R. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery. Select. Cancer Ther. 1991, 7:59-73.
52. Flanagan P.A., Kopeckova P., Kopecek J., Duncan R. Evaluation of antibody-N-(2-hydroxypropyl)-methacrylamide copolymer conjugates as targetable drug-carriers. 1. Binding, pinocytic uptake and intracellular distribution of transferrin and anti-transferrin receptor antibody-conjugates. Biochim. Biophys. Acta 1989, 993:83-91.
53. Seymour L.W., Duncan R., Strohalm J., Kopecek J. Effect of molecular weight of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mater. Res. 1987, 21:1341-1358.
54. Duncan R. Polymer therapeutics. Business Briefing, PharmTech 2001 2001, 178-184.
55. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
56. Terwogt J.M.M., Huinink W.W.T., Schellens J.H.M., Schot M., et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001, 12:315-323.
57. Sela M., Katchalski E. Biological properties of poly-α-amino acids. Adv. Protein Chem. 1959, 14:391-478.
58. Monsigny M., Roche A.C., Midoux P., Mayer R. Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes. Adv. Drug Del. Rev. 1994, 14:1-24.
59. Vercauteren R., Schacht E., Duncan R. Effect of the chemical modification of dextran on the degradation by rat liver lysosomal enzymes. J. Bioact. Biocomp. Polym. 1992, 7:346-357.
60. Franssen E.J.F., Moolenaar F., De Zeeuw D., Meijer D.K.F. Drug Targeting to the kidney with low-molecular weight proteins. Adv. Drug Del. Rev. 1994, 14:67-88.
61. Seymour L.W. Soluble polymers for lectin-mediated drug targeting. Adv. Drug Del. Rev. 1994, 14:89-112.
62. Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., Inoue S. Characterization and anticancer activity of the micelle forming polymeric anti-cancer drug adriamycinconjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 1990, 50:1693-1700.
63. Yokoyama M., Okano T., Sakurai Y., Ekimoto H., Shibazaki C., Kataoka K. Toxicity and anti-tumour activity against solid tumours of micelle-forming polymeric anti-cancer drug and its extremely long circulation in blood. Cancer Res. 1991, 51:3229-3236.
64. Yokoyama M. Block copolymers as drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9:213-248.
65. Duncan R. Selective endocytosis of macromolecular drug carriers. Controlled Drug Delivery: Fundamentals and Applications 1987, 581-607. Marcel Dekker, New York. 2nd edn. J.R. Robinson, V.H. Lee (Eds.).
66. Trouet A., Masquelier M., Baurain R., Deprez-De Campeneere D. A covalent linkage between daunorubicin and protein that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl Acad. Sci. USA 1982, 79:626-629.
67. Subr V., Strohalm J., Ulbrich K., Duncan R., Hume Z. Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)-methacrylamide] copolymer drug carriers in vitro and antitumour activity measured in vivo. J. Controlled Rel. 1992, 18:123-132.
68. De Marre A., Seymour L.W., Schacht E.H. Evaluation of the hydrolytic and enzymatic stability of macromolecular mitomycin C derivatives. J. Controlled Res. 1994, 31:89-97.
69. Kratz F., Beyer U., Schütte M.T. Drug-polymer conjugates containing acid-cleavable bonds carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16:245-288.
70. Kaneko T., Willner D., Monkovic I., Knipe J.O., et al. New hydrazone derivatives of adriamycin and their immunoconjugates. A correlation between acid stability and cytotoxicity. Bioconjugate Chem. 1991, 2:133-141.
71. Kratz F., Beyer U., Collery P., Lechenault F., et al. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin. Biol. Pharm. Bull. 1998, 21:56-61.
72. Coessens V., Schacht E., Domurado D. Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage. J. Controlled Rel. 1996, 38:141-150.
73. Shen W.C., Ryser H.J.P. Cis-aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 1981, 102:1048-1054.
74. Shen W.C., Ryser H.J.P., La Manna L. Disulfide spacer between methotrexate and poly(D-lysine). J. Biol. Chem. 1985, 260:10905-10908.
75. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymer: advantages of macromolecular therapeutics in vivo. Bioconj. Chem. 1992, 3:351-362.
76. Seymour L.W., Ulbrich K., Strohalm J., Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 1990, 39:1125-1131.
77. Takakura Y., Kitajima M., Matsumoto S., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. 1. Physicochemical characteristics and in vitro and in vivo antitumour activities. Int. J. Pharm. 1987, 37:135-143.
78. Sezaki H., Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1984, 1:1-38.
79. Ogino T., Inoue M., Ando Y., Arai H., Morino Y. Chemical modification of superoxide dismutase. Extension of plasma half-life of the enzyme through its reversible binding to circulating albumin. Int. J. Peptide Protein Res. 1988, 32:153-159.
80. Abuchowski A., McCoy J.R., Palczuk N.C., Es T.V., Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 1977, 252:3582-3586.
81. Kamisaki Y., Wada H., Yagura H., Matsushima A., Inada Y. Reduction in immunogenicity and clearance rate of Escherichia colil-asparaginase by modification with monomethoxypoly(ethylene glycol). J. Pharmacol. Exp. Ther. 1981, 216:410-414.
82. Li C.J., Miyamoto Y., Kojima Y., Maeda H. Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 1993, 67:975-980.
83. Suzuki M., Hori K., Abe I., Saito S., Sato H. A new approach to cancer chemotherapy: a selective enhancement of tumour blood flow with angiotensin II. J. Natl. Cancer Inst. 1981, 67:663-669.
84. Hori K., Suzuki M., Tanda S., Saito S., Shiozaki S., Zhang Q.H. Fluctuation in tumour blood flow under normotension and the effect of angiotensin II induced hypertension. Jpn. J. Cancer Res. 1991, 82:1309-1316.
85. Willmott N. Chemoembolisation in regional cancer chemotherapy: a rationale. Cancer Treat. Rev. 1987, 14:143-156.
86. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Drug Delivery Rev. 1991, 6:181-202.
87. Hirayama S., Sato F., Oda T., Maeda H. Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Jpn J. Antibiot. 1986, 39:815-822.
88. Maeda H. The tumour blood vessel as an ideal target for macromolecular anticancer agents. J. Controlled Rel. 1992, 19:315-324.
89. Konno T., Maeda H., Iwai K., Tashiro S., Mati S., Morinaga T., Mochinaga M., Hiraoka T., Yokoyama I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol. 1983, 19:1053-1065.
90. Konno T., Maeda H. Targeting chemotherapy of hepatocellular carcinoma: arterial administration of smancs/lipiodol. Neoplasms of the Liver 1987, 343-352. chap. 27, Springer-Verlag, New York. K. Okuda, K.G. Ishak (Eds.).
91. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellstrom K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261:212-215.
92. Wawrzynczak E.J., Derbyshire E.J. Immunotoxins: the power and the glory. Immunology Today 1992, 13:381-383.
93. Vitetta E.S., Stone M., Amlot P., Fay J., et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991, 51:4052-4058.
94. Wang J.M., Kumar S., Pye D., Van Agthoven A.J., Krupinski J., Hunter R.D. A monoclonal antibody detects heterogenicity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 1993, 54:363-370.
95. Burrows F.J., Thorpe P.E. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc. Natl. Acad. Sci. 1993, 90:8996-9000.
96. Bagshawe K.D., Springer C.J., Searle F., Antoniw P., Sharma S.K., Melton R.G., Sherwood R.F. A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer 1988, 58:700-703.
97. Springer C.J., Bagshawe K.D., Sharma S.K., Searle F., et al. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 1991, 27:1361-1366.
98. Senter P.D., Su P.D.D., Katsuragi T., Sakai T., et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconjugate Chem. 1991, 2:447-451.
99. Sharma, S.K., Bagshawe, K.D., Springer, C.J., Burge, P.J., et al. Antibody directed enzyme prodrug therapy (ADEPT): a three-phase system. Disease Markers9: 225-231.
100. Goldstein I.J., Hugues R.C., Monsigny M., Osawa T., Sharon N. What should be called a lectin?. Nature 1980, 285:66.
101. Ashwell G., Harford J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 1982, 51:531-554.
102. Sharon N., Lis H. Lectins as cell recognition molecules. Science 1989, 246:227-234.
103. Monsigny M., Roche A.C., Midoux P. Endogenous lectins and drug targeting. Ann. NY Acad. Sci. 1988, 551:399-414.
104. De Duve C., De Barsy T., Poole B., Trouet A., et al. Lysosomotropic agents. Biochem. Pharmacol. 1974, 23:2495-2531.
105. Schwartz A.L. The hepatic asialoglycoprotein receptor. CRC Crit. Rev. Biochem. 1984, 16:207-233.
106. Vansteenkiste S., Schacht E., Duncan R., Seymour L., Pawluczyk I., Baldwin R. Fate of glycosylated dextrans after in vivo administration. J. Controlled Rel. 1991, 16:91-100.
107. Vansteenkiste S., De Marre A., Schacht E. Synthesis of glycosylated dextrans. J. Bioact. Compat. Polymers 1992, 7:4-14.
108. Anderson D., Vansteenkiste S., Schacht E.H., Sen S.V., Seymour L.W. In vitro binding specificity of glycosylated dextrans to the asialoglycoprotein receptor of primary hepatocytes. Eur. J. Pharm. 1994, 3:339-345.
109. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl J Med. 1991, 324:1-8.
110. Yancopoulos G.D., Klagsbrun M., Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998, 93:661-664.
111. Eliceiri B.P., Cheresh D.A. Adhesion events in angiogenesis. Curr Opin. Cell Biol. 2001, 13:563-568.
112. Martiny-Baron G., Marme D. VEGF-mediated tumor angiogenesis - a new target for cancer-therapy. Curr. Opin. Biotechnol. 1995, 6:675-680.
113. 3 antagonist promote tumor-regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
114. Humphries M.J., Olden K., Yamada K.M. A synthetic peptide from fibronectin inhibits experimental metastasis of muring melanoma cells. Science 1986, 233:467-470.
115. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
116. Maeda M., Izuno Y., Kawasaki K., Kaneda Y., et al. Amino acids and peptides XXX. Preparation of Arg-Gly-Asp (RGD) hybrids with poly(ethylene glycol) analogs and their antimetastatic effect. Chem. Pharm. Bull. 1997, 45:1788-1792.
117. Cooke J.P., Losordo D.W. Nitric oxide and angiogenesis. Circulation 2002, 105:2133-2135.
118. Fridovich L. Quantitative aspects of the production of superoxide anion radical by milk xanthine oxidase. J. Biol. Chem. 1970, 245:4053-4057.
119. Sawa T., Wu J., Akaike T., Maeda H. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue. Cancer Res. 2000, 60:666-671.
120. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and antitumour agent SMANCS. Cancer Res. 1986, 46:6387-6392.
121. Jain R.K. Vascular and interstitial barriers to the delivery of therapeutic agents in tumours. Cancer Metast. Rev. 1991, 9:253-266.
122. Senger D.R., Van de Water L., Brown I.F., Nagy J.A., Yeo K.T., et al. Vascular permeability factor in tumour biology. Cancer Metast. Rev. 1993, 12:303-324.
123. Berstein A., Hurwitz E., Maron R., Arnon R., et al. Higher antitumour efficacy of daunomycin when linked to dextran: in vivo and in vitro studies. J. Natl Cancer Inst. 1978, 60:379-384.
124. Zunino F., Pratesi G., Pezzoni G. Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side chain of the drug. Cancer Treat. Reps. 1987, 71:367-373.
125. Trouet A., Jolles G. Targeting of daunorubicin by association with DNA or proteins: a review. Sem. Oncol. 1984, 11:64-73.
126. Seymour L.W. Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev. Therapeut. Drug Carr. Syst. 1992, 9:135-187.
127. Cassidy J., Duncan R., Morrison G.J., Strohalm J., et al. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 1989, 38:875-880.
128. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., et al. Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Rel. 1992, 18:123-132.
129. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., et al. Tumourtropism and anticancer afficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 1994, 70:636-641.
130. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 1995, 31A:766-770.
131. Moscow J.A., Cowan K.H. Multidrug resistance. J. Natl Cancer 1988, 80:14-20.
132. Kopecek J., Kopeckova P., Minko T., Zheng-Rong L. HPMA copolymer-anticancer drug conjugates: design, activity and mechanism of action. Eur. J. Pharma. Biopharm. 2000, 50:61-81.
133. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., et al. Doxorubicia-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 1992, 44:509-517.
134. Warren L., Jardilier J.C., Malarska A., Akeli M.G. Increased accumulation of drugs in multidrug resistant cell induced by liposomes. Cancer Res. 1992, 52:3241-3245.
135. Ohkawa K., Hatano T., Yamada K., Joh K., et al. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 1993, 53:4238-4242.
136. Stastny M., Strohalm J., Plocova D., Ulbrich K., Rihova B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 1999, 35:459-466.
137. Minko T., Kopeckova P., Pozharov V., Kopecek J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in human ovarian carcinoma cell line. J. Controlled Rel. 1998, 54:223-233.
138. Tijerina M., Fowers K.D., Kopeckova P., Kopecek J. Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e(6) does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials 2000, 21:2203-2210.
139. Maher S., Toomey D., Condron C., Bouchier-Hayes D. Activation induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol. Cell Biol. 2002, 80:131-137.
140. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365.
141. Daniel P.T., Scholz C., Westermann J., Dorken B., Pezzutto A. Dendritic cells prevent CD95-mediated T lymphocyte death through costimulatory signals. Gene Ther. Cancer 1998, 28:173-177.
142. Restifo N. Not so Fas: re-evaluating the mechanism of immune privilege and tumor escape. Nat. Med. 2000, 6:493-495.
143. Krammer P.H., Dhein J., Walczak H., Behermann I., et al. The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev. 1994, 142:175-191.
144. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 1999, 20:46-52.
145. O'Connell J., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 1996, 184:1075-1082.
146. Hahne M., Rinoldi D., Schroter M., Romero P., et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
147. Strand S., Hofmann W.J., Hug H., Muller M., et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion?. Nat. Med. 1996, 2:1361-1366.
148. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997, 57:1007-1012.
149. Von Bernstorff W., Spanjaard R.A., Chan A.K., Lockhart D.C., et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas(APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999, 125:73-84.
150. Bennett M.W., O'Connell J., O'Sullivan G.C., Brady C., et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 1998, 160:5669-5675.
151. Mitsiades N., Poulaki V., Kotoula V., Leone A., Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloprotease. Am. J. Pathol. 1998, 153:1947-1956.
152. Friesen C., Herr I., Krammer P.H., Debatin K.-M. Involvement of the CD95 (Apo-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 1996, 2:574-577.
153. Walker P.R., Saas P., Dietrich P.-Y. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back - commentary. J. Immunol. 1997, 15:4521-4524.
154. Friesen C., Fulda S., Debatin K.-M. Cytotoxic drugs and the CD95 pathways. Leukemia 1999, 13:1854-1858.
155. Rihova B., Strohalm J., Hoste K., Jelinkova M., et al. Immunoprotective therapy with targeted anticancer drugs. Macromol. Symp. 2001, 172:21-28.
156. Callant D., Schacht E. Macromolecular prodrugs of 5-aminosalicylic acid, 1. Azo-conjugates. Makromol. Chem. 1990, 191:529-536.
157. Schacht E., Gevaert A., Kenawy E.R., Molly K., Verstraete W., et al. Polymers for colon specific drug delivery. J. Controlled Rel. 1996, 39:327-338.
158. Kopeckova P., Kopecek J. Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers by azoreductases in vitro. Makromol. Chem. 1990, 191:2037-2045.